Skip to main content

Table 1 DOTs per 1000 patient-days of oral antibiotics in the Department of Oral and Maxillofacial Surgery

From: Effect of educational intervention on the appropriate use of oral antimicrobials in oral and maxillofacial surgery: a retrospective secondary data analysis

  Outpatients Inpatients
2013 2018 2013 2018
First- and second-generation cephalosporinsa 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Third-generation cephalosporinsb 218 (197, 233) 2.5 (1.4, 3.3)i 170 (142, 199) 0 (0, 0)i
Macrolides 169 (158, 179) 70.8 (60.2, 81.4)i 59.4 (47.6, 73.8) 28.3 (11.6, 32.9)i
Short-actingc 0 (0, 0)   0 (0, 0) 0 (0, 49.4)j
Medium-actingd 138 (125, 162) 0 (0, 0) 41.9(19.2, 49.6) 0 (0, 5.0)i
Long-actingee 27.2 (19.5, 37.0) 52.9 (41.0, 68.7)i 18.8 (17.6, 25.6) 10.5 (5.5, 19.1)i
Quinolones 57.0 (41.7, 80.9) 15.9 (14.0, 19.4)i 21.4 (13.3, 32.5) 24.5 (14.6, 32.9)
Second-generationf 9.4 (8.1, 16.9) 35.6 (28.6, 40.8)i 16.6 (7.9, 32.5) 0 (0, 1.9)i
Third-generationg 47.7 (34.1, 68.8) 7.3 (4.4, 10.2) 0 (0, 0) 19.5 (14.6, 28.2)j
Penicillins 25.3 (18.9, 32.3) 24.9 (23.5, 32.5)i 7.1 (6.0, 12.7) 115 (79.8, 118)j
Amoxicillin 25.3 (18.9, 32.3) 185 (170, 195)j 7.1 (6.0, 12.7) 103 (74.7, 116)
Clavulanate/amoxicillin 0 (0, 0) 181 (168, 195) 0 (0, 0) 0 (0, 12.7)
Clindamycin 0 (0, 1.5) 0.8 (0, 7.0) 0 (0, 0) 13.4 (10.5, 19.4)j
Tetracyclinesh 0 (0, 0) 2.5 (0. 5.1) 0 (0, 1.1) 0 (0, 4.6)
Metronidazole 0 (0, 0) 0 (0, 2.0)j 0 (0, 0) 12.6 (0, 18.9)j
Fosfomycin 0 (0, 0) 5.1 (0, 13.9)j 0 (0, 0) 0 (0, 0)
Others   0 (0, 0)   
Sulfamethoxazole/ 0 (0, 0)   0 (0, 0) 0 (0, 5.1)
Trimethoprim   0 (0, 0)   
Total 464 (451, 502) 310 (282, 345)i 278 (227, 319) 211 (176, 250)i
  1. Median (first quartile, third quartile)
  2. DOTs days of therapy
  3. aCefalexin, cefaclor
  4. bCefcapene pivoxil, cefditoren–pivoxil, cefteram–pivoxil, cefdinir
  5. cErythromycin
  6. dClarithromycin, roxithromycin
  7. eAzithromycin
  8. fLevofloxacin, ciprofloxacin, tosufloxacin, ofloxacin
  9. gSitafloxacin, garenoxacine, moxifloxacin, prulifloxacin
  10. hMinocycline, doxycycline
  11. iDOTs in 2018 decreased significantly compared to those in 2013
  12. jDOTs in 2018 increased significantly compared to those in 2013